Table TDI-24. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2004

Table TDI-24. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2004: the combination of cannabis, opioids, cocaine or other stimulants as primary drug type with a secondary drug – Part (i) All clients with opioids as primary drug: numbers reporting the stated drug as secondary
Country	Opioids	Cocaine	Other stimulants	Hypnotics, sedatives	Hallucinogens	Volatile inhalants	Cannabis	Alcohol	Others	Total
Czech Republic	79	7	276	20	6	13	174	14	3	592
Germany	0	0	0	0	0	79	7789	5379	206	13453
Greece	81	615	270	865	171	2	1227	102	89	3422
Italy	0	38259	9808	7536	3675	88	46902	17182	276	123726
Cyprus	0	51	19	11	4	0	99	0	0	184
Netherlands	0	1232	0	0	0	0	93	250	23	1598
Slovenia	0	0	0	0	0	0	0	0	0	0
Slovakia	0	16	95	9	8	6	64	30	0	228
Finland	0	3	157	173	0	0	150	18	1	502
United Kingdom	12131	38239	5168	19000	92	30	10142	1722	320	86844
Bulgaria	130	66	74	22	2	2	113	7	3	419

Total	12421	78488	15867	27636	3958	220	66753	24704	921	230968
Notes: Data on secondary drug use are only collected for all treatment clients and not separately for new treatment clients. Opioids include: heroin, methadone, other opioids; cocaine includes: cocaine CIH, crack cocaine; stimulants include: amphetamines, MDMA and derivates, other stimulants: cannabis can include herbal cannabis or cannabis resin. For each client up to four secondary drugs can be reported A number of the clients report using the same drug both as primary and secondary drug, particularly for cannabis. Clients may report using different sub-types of the same substance, as defined in the TDI Protocol for the drugs categories. The greater part of clients using cannabis both as primary and secondary drug comes from Germany See also 'General notes for interpreting data' on the Explanatory notes and help page. Source: 2005 Reitox national reports